Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Phytocannabinoids, particularly cannabidiol (CBD), have gained research interest as potential adjuncts in the treatment of addiction, including tobacco smoking and chewing. While their use is not rooted in traditional medicine for these specific addictions, there is emerging scientific evidence, primarily from preclinical and early clinical studies, suggesting a possible benefit. For example, a small double-blind, placebo-controlled pilot study published in Addictive Behaviors (2013) found that smokers given CBD inhalers reduced the number of cigarettes smoked by about 40% compared to placebo over one week. Animal studies have also shown that CBD may disrupt the reconsolidation of drug-related memories and reduce cue-induced cravings, possibly by modulating the endocannabinoid system and serotonin signaling. However, the overall quality and quantity of evidence remain limited, with most studies having small sample sizes, short durations, and methodological challenges. There is also a lack of robust data addressing other phytocannabinoids (like THC) in this context, and concerns about the abuse potential of certain cannabinoids. Major addiction guidelines do not currently endorse phytocannabinoids as standard treatment for tobacco dependence. Thus, while there is preliminary scientific interest and some early evidence, larger, well-controlled trials are necessary to establish efficacy and safety.

More about phytocannabinoids
More about Addictions (tobacco smoking or chewing)

Other ingredients used for Addictions (tobacco smoking or chewing)

Other health conditions supported by phytocannabinoids

Products containing phytocannabinoids